Recommencement of ZIRCON Phase III Trial Recruitment in EU
Telix Pharmaceuticals Limited announces that the Company’s ZIRCON phase III trial of TLX250-CDx has recommenced patient recruitment in…
Read moreNews & Views
Presentation to Jefferies Virtual Healthcare Conference
Telix Pharmaceuticals Limited has today announced that Group CBO Dr. David Cade presented at Jefferies Virtual Healthcare…
Read more
Telix Pharmaceuticals Appoints Dr Colin Hayward as Chief Medical Officer
News,
Telix Pharmaceuticals announces that Dr Colin Hayward has joined Telix’s executive leadership team in the role of Chief Medical Officer…
Read more
Telix presents IPAX-1 study in glioblastoma treatment at ASCO 2020
Telix Pharmaceuticals is pleased to announce that the IPAX-1 study will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program to be held May 29…
Read more
Telix Pharmaceuticals and Pharmalogic Enter US Distribution Agreement for Prostate Cancer Imaging
Telix Pharma (U.S.) announces it has entered into a commercial distribution agreement with Pharmalogic Holdings…
Read more
Telix Pharmaceuticals Granted July Pre-IND Meeting with US FDA for Phase III ProstACT Study
Telix has been granted a Type B pre-IND meeting with the FDA in relation to the Company’s planned Phase III ProstACT trial for…
Read more
Telix AGM – Chairman and CEO Addresses
Telix is pleased to provide the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting of…
Read more
ARTMS and Telix Pharmaceuticals Announce Manufacturing Collaboration
ARTMS Products Inc. and Telix Pharmaceuticals Limited have entered into a development collaboration agreement…
Read more
The Seneffe Manufacturing Site – Telix’s Next Big Move in Europe
Telix’s CEO Chris Behrenbruch comments on the Company’s next big move in Europe : the Seneffe manufacturing…
Read more
Telix Submits European Marketing Authorisation Application for Prostate Cancer Imaging Product
Telix has submitted a marketing authorisation application (MAA) in Europe for…
Read more